Melasma — acquired hypermelanosis predominantly affecting sun-exposed facial areas, particularly in women of reproductive age with Fitzpatrick skin types III–VI — is one of the most challenging, frequently recurrent, and distressing dermatological conditions to treat. The pathophysiology involves UV-stimulated melanocyte hyperactivity combined with hormonal drivers (estrogen, progesterone), vascular components (V-melasma subtype), and stem cell involvement — explaining why sun protection is the non-negotiable foundation and why recurrence after treatment is near-universal without maintenance.
First-Line Treatment: The Triple Combination and Hydroquinone
Kligman's triple combination cream (fluocinolone acetonide 0.01% + hydroquinone 4% + tretinoin 0.05%): the most evidence-supported melasma treatment. Multiple RCTs show 60–80% complete clearing rates versus 30–40% for HQ alone — the corticosteroid reduces HQ irritation and adds anti-inflammatory effect, while tretinoin enhances HQ penetration and epidermal turnover. Available by prescription (Tri-Luma). Duration: 8 weeks initial course, then maintenance to prevent recurrence. Hydroquinone 4% alone: 50–65% improvement in 12-week RCTs. Mechanism: competitive inhibitor of tyrosinase (the rate-limiting enzyme in melanin synthesis) in active melanocytes. Not a bleaching agent — it specifically inhibits melanin production rather than destroying melanocytes. Despite controversies about long-term use (ochronosis risk with ≥4 years continuous use — rare), HQ remains the gold standard comparator agent for melasma and is approved by FDA at 4% OTC in many countries.
Emerging and Alternative Treatments
Tranexamic acid (TXA): competitive inhibitor of plasminogen activator → reduces UV-induced prostaglandin E2 → reduces melanocyte stimulation. Oral TXA 250mg twice daily: four RCTs showing equivalent efficacy to HQ 4% with excellent tolerability — becoming a first-line alternative in settings where long-term HQ is avoided. Topical TXA 2–5%: emerging evidence, generally less effective than oral but with better safety profile than many topical alternatives. Cysteamine 5% cream: antioxidant mechanism inhibiting melanin synthesis — 2020 RCT showed comparable efficacy to HQ 4% without ochronosis risk. A notable option for long-term maintenance. Laser cautions: fractional laser and IPL for melasma are controversial — can induce hyperpigmentation flares (PIH) in darker skin types if performed without adequate topical preparation and UV protection. Tranexamic acid pre-treatment before laser reduces PIH risk. Our skin care catalog includes complementary skincare products supporting comprehensive hyperpigmentation management protocols.
